Professor Ning-NingLu: Precision Radiotherapy in Urologic Malignancies: State-of-the-Art Clinical Practices and Emerging Strategies

Professor Ning-NingLu: Precision Radiotherapy in Urologic Malignancies: State-of-the-Art Clinical Practices and Emerging Strategies

2025.12.12
With China’s population undergoing demographic aging and growing public awareness of cancer screening, the clinical need for the management of urologic malignancies is steadily increasing. Radiotherapy, a mainstay of oncologic treatment, has evolved rapidly—progressing from old techniques to intensity‑modulated radiotherapy (IMRT), and from conventional fractionation regimens to stereotactic body radiation therapy (SBRT). Precision radiotherapy is now emerging as a pivotal modality in the management of urologic cancers. Professor Ningning Lu, affiliated to the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, has dedicated years to the field of precision radiotherapy for urologic tumors, amassing substantial clinical expertise and a robust research portfolio. UroStream invited Professor Lu to deliver an in-depth review of the clinical applications of precision radiotherapy in urologic malignancies, thereby providing evidence-based insights and practical guidance for clinicians.
ESMO Asia 2025 | Professor George Lau: HR 0.60！STRIDE regimen Chinese population data impressively unveiled, dual immunotherapy efficacy significantly

ESMO Asia 2025 | Professor George Lau: HR 0.60！STRIDE regimen Chinese population data impressively unveiled, dual immunotherapy efficacy significantly

2025.12.11
From December 5 to 7, 2025, the highly anticipated European Society for Medical Oncology Asia Congress (ESMO Asia 2025) was grandly held in Singapore. During the Mini Oral Session: Gastrointestinal Tumours, Professor George Lau, Chairman of the Hong Kong Humanity Medical Group and Director of the Humanity Medical Clinical Research CenterSenior Consultant in Gastroenterology and Hepatology, Humanity and Health Medical Center, Principal Investigator of the Humanity and Health Clinical Trial Center, as well as a physician Honorary Professor and Senior Consultant at Zhongshan Hospital Affiliated to Fudan University, was invited to deliver an oral presentation. For the first time, he shared the research data on the treatment of Asian patients with unresectable hepatocellular carcinoma (HCC) using Tremelimumab in combination with Durvalumab. This study is based on a sample that more closely reflects the epidemiological characteristics and disease spectrum of Asian patients, providing high-quality evidence-based medical evidence with targeted relevance. It lays a solid foundation for optimizing and advancing the individualization and precision of liver cancer treatment strategies in this region.
ASH China Voice | Jia Wei’s Team Presents Seven Studies at ASH 2025, Advancing Multi-Dimensional Exploration of Therapeutic Bottlenecks in Hematologic

ASH China Voice | Jia Wei’s Team Presents Seven Studies at ASH 2025, Advancing Multi-Dimensional Exploration of Therapeutic Bottlenecks in Hematologic

2025.12.10
From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting was held in Orlando. As the world’s most influential and comprehensive academic event in hematology, ASH annually gathers tens of thousands of experts to present breakthroughs spanning basic research to clinical innovation. This year, the team led by Professor Jia Wei of Tongji Hospital, Huazhong University of Science and Technology, had seven studies accepted—one oral presentation and six posters—covering CAR-T therapy, multi-omics analysis and immunotherapy. These studies collectively illustrate a full-spectrum innovation pipeline from mechanistic discovery to translational clinical application. Hematology Frontier summarizes the key findings below and presents Professor Wei’s commentary on their broader significance.